Showing results (191-200 of 214) with videos related to

Sort By:
Pageof 22
Cell Genomics|December 27, 2021
Machine learning enables new insights into genetic contributions to liver fat accumulationMary E Haas, James P Pirruccello, Samuel N Friedman, et al.
The Journal of Infectious Diseases|June 6, 2018
Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus CoinfectionAnna Lidofsky, Jacinta A Holmes, Eoin R Feeney, et al.
The Lancet. HIV|October 16, 2019
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trialTakara L Stanley, Lindsay T Fourman, Meghan N Feldpausch, et al.
Journal of Hepatology|October 3, 2021
ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLDKathleen E Corey, Rebecca Pitts, Michelle Lai, et al.
Hepatology Communications|October 25, 2022
Risk factors for cardiovascular disease among individuals with hepatic steatosisJulia Karády, Maros Ferencik, Thomas Mayrhofer, et al.
Clinical Transplantation|February 9, 2016
Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter studyJessica L Mueller, Lindsay Y King, Kara B Johnson, et al.
The Journal of Clinical Investigation|October 31, 2017
Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetesJohn F O'Sullivan, Jordan E Morningstar, Qiong Yang, et al.
Hepatology Communications|September 24, 2021
Distinct Hepatic Gene-Expression Patterns of NAFLD in Patients With ObesitySonu Subudhi, Hannah K Drescher, Laura E Dichtel, et al.
Cell Metabolism|December 15, 2023
ChREBP is activated by reductive stress and mediates GCKR-associated metabolic traitsCharandeep Singh, Byungchang Jin, Nirajan Shrestha, et al.
Pageof 22